Rivastigmine
Product Images NDC 51956-0002

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 51956-0002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 01)

Chemical structure diagram of rivastigmine showing its molecular formula with two nitrogen atoms, a benzene ring, and multiple methyl groups. The diagram depicts the specific bonding and arrangement of atoms within the rivastigmine molecule.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 02)

An illustration showing a four-layer structure labeled as Layer 1 through Layer 4. The diagram depicts the layered composition likely related to a pharmaceutical formulation or packaging.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 03)

A line graph depicting rivastigmine plasma concentration (ng/mL) over 24 hours for three dosing groups: 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The x-axis represents time in hours, and the y-axis represents rivastigmine concentration. Each dose group shows a peak concentration followed by a decline, with higher doses reaching higher peak levels.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 04)

A line graph depicting least square means change in ADAS-Cog rating from baseline over 24 weeks of treatment. Four treatment groups are shown: 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. The y-axis represents changes indicating clinical improvement (negative values) or clinical decline (positive values). The 17.4 mg/24 hours group shows the greatest clinical improvement by week 24, while placebo shows clinical decline.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 05)

Bar chart showing the distribution of ADCS-CGIC ratings among patients treated with Rivastigmine at different dosages (17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID) compared to placebo. The y-axis represents the percentage of patients, and the x-axis shows ADCS-CGIC categories ranging from markedly improved to markedly worse.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 06)

A line graph comparing the ADCS-IADL change from baseline (LS means SEM) over 48 weeks of treatment between Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr. The x-axis shows weeks of treatment from 0 to 52, and the y-axis measures clinical improvement to decline. The higher dose shows less clinical decline compared to the lower dose over time, with statistically significant differences at multiple points.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 07)

A line graph comparing ADAS-Cog change from baseline over 48 weeks between Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr. The y-axis shows change indicating clinical improvement and decline, while the x-axis represents weeks of treatment. The 13.3 mg dose shows less clinical decline compared to 9.5 mg throughout the study period.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 08)

A line graph comparing the least squares mean change with standard error for two Rivastigmine Transdermal System dosages (13.3 mg/24 hr and 4.6 mg/24 hr) over 24 weeks of treatment. The graph shows clinical improvement and decline on the vertical axis, with statistically significant differences at weeks 16 and 24 in favor of the 13.3 mg/24 hr dosage.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 09)

Line graph showing least squares mean change with standard errors over 24 weeks of treatment for Rivastigmine Transdermal System at 13.3 mg/24 hr and 4.6 mg/24 hr doses. The vertical axis represents LS mean change and the horizontal axis shows weeks of treatment. Data points indicate clinical improvement or decline, with statistically significant differences marked at weeks 16 and 24.*

FDA Label Image

Figure A (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 10)

Instructional diagram illustrating the components and packaging of the Rivastigmine Transdermal System by Zydus Lifesciences Limited. It shows a labeled pouch containing one transdermal system, the system with protective liners on a square backing, and a detailed view of the patch with adhesive containing medicine, protective liners, and outside backing.*

FDA Label Image

Figure B (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 11)

An instructional diagram showing possible application sites on the body for a Rivastigmine patch by Zydus Lifesciences Limited. It depicts areas for patch placement on the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back, highlighted by striped boxes on front, side, and back views of the torso and arms.*

FDA Label Image

Figure C (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 12)

Illustration showing a hand holding a Rivastigmine Transdermal System package while a pair of scissors is positioned to cut along a dotted line marked on the package. The image demonstrates how to open the transdermal system packaging safely using scissors. The label indicates the product name Rivastigmine Transdermal System by Zydus Lifesciences Limited and specifies that it contains one system for transdermal use only.*

FDA Label Image

Figure D (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 13)

Instructional illustration showing two hands holding a sealed blister pack containing a single round tablet, with arrows indicating the action of peeling back the foil to access the tablet inside.*

FDA Label Image

Figure E (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 14)

An instructional illustration showing hands peeling off protective liners from a round transdermal patch with a sticky surface. Labels identify the protective liners being removed and the sticky surface of the transdermal system. The image relates to the handling or application of a transdermal patch, possibly for Rivastigmine by Zydus Lifesciences Limited.*

FDA Label Image

Figure F (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 15)

An instructional illustration depicting the application of a transdermal patch on the upper back of a person. Two hands are shown placing the patch onto the skin, demonstrating proper placement and adherence technique.*

FDA Label Image

Figure G (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 16)

An instructional diagram showing a person from the back with a hand placed on the upper shoulder area, indicating the application site for a transdermal patch or topical medication.*

FDA Label Image

Figure H (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 17)

An instructional illustration showing two hands applying a patch to the upper chest area. One hand is pressing the patch onto the skin while the other hand is peeling off the backing in a curved motion, indicating the application process for a transdermal patch.*

FDA Label Image

Figure I (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 18)

Instructional illustration showing disposal steps for Rivastigmine transdermal system patches. It depicts folding the sticky sides of the patch together, sliding the folded patch into an empty pouch, and placing the pouch into a trash bin with a reminder to keep it away from children and pets.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 19)

Label of Rivastigmine Transdermal System delivering 4.6 mg over 24 hours. The label indicates Rx only use, for transdermal application, contains 30 systems, and is labeled by Zydus Lifesciences Limited.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 20)

Rivastigmine Transdermal System 9.5 mg/24 hours label from Zydus Pharmaceuticals. The label indicates prescription-only status, with packaging containing 30 transdermal systems for transdermal use.*

FDA Label Image

Rivastigmine Transdermal System (D8a0757b 8b66 43f1 A3e7 7c91ecdcbee6 21)

Label of Rivastigmine Transdermal System delivering 13.3 mg/24 hours, intended for transdermal use only. The packaging indicates a quantity of 30 systems and features the Zydus Pharmaceuticals logo, labeled by Zydus Lifesciences Limited. Includes an Rx only designation and NDC 51956-0003-7.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.